Navidea Biopharmaceuticals Inc Stock

$0.33+0.00 (+0%)
Updated Mar 17, 2023
NAVB Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
Mar 21, 2023
Next Dividend

NAVB Overview

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a collaboration agreement with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NAVB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NAVB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NAVB is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
NAVB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more NAVB due diligence checks available for Premium users.

Be the first to know about important NAVB news, forecast changes, insider trades & much more!


NAVB price to earnings (PE)

For valuing profitable companies with steady earnings

NAVB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

NAVB's financial health

Profit margin

Net Income
Profit Margin
NAVB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NAVB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
NAVB's short-term liabilities ($8.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NAVB's short-term assets ($5.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NAVB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NAVB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

NAVB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NAVB vs Biotech Stocks

TickerMarket Cap1d %P/EP/B

Navidea Biopharmaceuticals Stock FAQ

What is Navidea Biopharmaceuticals's quote symbol?

NYSEMKT: NAVB) Navidea Biopharmaceuticals trades on the NYSEMKT under the ticker symbol NAVB. Navidea Biopharmaceuticals stock quotes can also be displayed as NYSEMKT: NAVB.

If you're new to stock investing, here's how to buy Navidea Biopharmaceuticals stock.

What is the 52 week high and low for Navidea Biopharmaceuticals (NYSEMKT: NAVB)?

(NYSEMKT: NAVB) Navidea Biopharmaceuticals's 52-week high was $1.24, and its 52-week low was $0.16. It is currently -73.39% from its 52-week high and 106.25% from its 52-week low.

How much is Navidea Biopharmaceuticals stock worth today?

(NYSEMKT: NAVB) Navidea Biopharmaceuticals currently has 32,364,362 outstanding shares. With Navidea Biopharmaceuticals stock trading at $0.33 per share, the total value of Navidea Biopharmaceuticals stock (market capitalization) is $10.68M.

Navidea Biopharmaceuticals stock was originally listed at a price of $120.00 in Dec 31, 1997. If you had invested in Navidea Biopharmaceuticals stock at $120.00, your return over the last 25 years would have been -99.73%, for an annualized return of -21.01% (not including any dividends or dividend reinvestments).

How much is Navidea Biopharmaceuticals's stock price per share?

(NYSEMKT: NAVB) Navidea Biopharmaceuticals stock price per share is $0.33 today (as of Mar 17, 2023).

What is Navidea Biopharmaceuticals's Market Cap?

(NYSEMKT: NAVB) Navidea Biopharmaceuticals's market cap is $10.68M, as of Mar 21, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Navidea Biopharmaceuticals's market cap is calculated by multiplying NAVB's current stock price of $0.33 by NAVB's total outstanding shares of 32,364,362.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.